Enliven Therapeutics ELVN Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's other operating expenses?
- Enliven Therapeutics (ELVN) reported other operating expenses of $27.82M in Q1 2026.
- How has Enliven Therapeutics's other operating expenses changed year-over-year?
- Enliven Therapeutics's other operating expenses decreased by 12.2% year-over-year, from $31.69M to $27.82M.
- What is the long-term trend for Enliven Therapeutics's other operating expenses?
- Over 4 years (2021 to 2025), Enliven Therapeutics's other operating expenses has grown at a 23.5% compound annual growth rate (CAGR), from $51.44M to $119.66M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.